223 related articles for article (PubMed ID: 30246661)
21. Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study.
Majewski S; Szewczyk K; Białas AJ; Miłkowska-Dymanowska J; Górski P; Piotrowski WJ
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581688
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
[TBL] [Abstract][Full Text] [Related]
23. What has been learned by cytokine targeting of asthma?
Busse WW; Viswanathan R
J Allergy Clin Immunol; 2022 Aug; 150(2):235-249. PubMed ID: 35934678
[TBL] [Abstract][Full Text] [Related]
24. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma.
Matera MG; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Discov; 2023; 18(9):951-963. PubMed ID: 37387523
[TBL] [Abstract][Full Text] [Related]
25. Alarmins and immunity.
Yang D; Han Z; Oppenheim JJ
Immunol Rev; 2017 Nov; 280(1):41-56. PubMed ID: 29027222
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte development, tissue recruitment, and function during allergic inflammation.
Radtke D; Voehringer D
Eur J Immunol; 2023 Aug; 53(8):e2249977. PubMed ID: 36929502
[TBL] [Abstract][Full Text] [Related]
27. Targeting TSLP in Asthma.
Parnes JR; Molfino NA; Colice G; Martin U; Corren J; Menzies-Gow A
J Asthma Allergy; 2022; 15():749-765. PubMed ID: 35685846
[TBL] [Abstract][Full Text] [Related]
28. The last step to achieve barrier damage control.
Baglivo I; Colantuono S; Lumaca A; Papa A; Gasbarrini A; Caruso C
Front Immunol; 2024; 15():1354556. PubMed ID: 38415254
[TBL] [Abstract][Full Text] [Related]
29. Alarmin Cytokines as Central Regulators of Cutaneous Immunity.
Hasegawa T; Oka T; Demehri S
Front Immunol; 2022; 13():876515. PubMed ID: 35432341
[TBL] [Abstract][Full Text] [Related]
30. Emerging Biologics in Severe Asthma.
Pavord ID; Hilvering B; Shrimanker R
Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
[TBL] [Abstract][Full Text] [Related]
31. TSLP and HMGB1: Inflammatory Targets and Potential Biomarkers for Precision Medicine in Asthma and COPD.
Furci F; Murdaca G; Pelaia C; Imbalzano E; Pelaia G; Caminati M; Allegra A; Senna G; Gangemi S
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830972
[TBL] [Abstract][Full Text] [Related]
32. ATP functions as a primary alarmin in allergen-induced type 2 immunity.
O'Grady SM; Kita H
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1369-C1386. PubMed ID: 37842751
[TBL] [Abstract][Full Text] [Related]
33. [Tezepelumab (Tezspire®) : new biological treatment of severe asthma].
Schleich F; Sabbe M; Moermans C; Louis R
Rev Med Liege; 2024 Jan; 79(1):60-64. PubMed ID: 38223972
[TBL] [Abstract][Full Text] [Related]
34. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M; Kabata H; Irie M; Fukunaga K
Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.
Plaza V; Cañete C; Domingo C; Martínez Rivera C; Muñoz X
Open Respir Arch; 2023; 5(2):100231. PubMed ID: 37496871
[TBL] [Abstract][Full Text] [Related]
36. [Tezepelumab: a new option for the treatment of severe asthma].
Maldonado-Ríos VA; Ardila-Herrera JC; Galicia-Sánchez LM; Celis-Preciado CA
Rev Med Inst Mex Seguro Soc; 2023 Nov; 61(6):841-848. PubMed ID: 37995367
[TBL] [Abstract][Full Text] [Related]
37. Anti-alarmin asthma therapies: where do we go from here?
Sulaiman I; Gauvreau GM
J Bras Pneumol; 2023 Jul; 49(3):e20230220. PubMed ID: 37493796
[No Abstract] [Full Text] [Related]
38. Biologics for allergic and immunologic diseases.
Morita H; Matsumoto K; Saito H
J Allergy Clin Immunol; 2022 Oct; 150(4):766-777. PubMed ID: 36058723
[TBL] [Abstract][Full Text] [Related]
39. Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis.
Ando K; Fukuda Y; Tanaka A; Sagara H
Cells; 2022 Feb; 11(5):. PubMed ID: 35269440
[TBL] [Abstract][Full Text] [Related]
40. Ferulic acid supresses Th2 immune response and prevents remodeling in ovalbumin-induced pulmonary allergy associated with inhibition of epithelial-derived cytokines.
Sin Singer Brugiolo A; Carvalho Gouveia AC; de Souza Alves CC; de Castro E Silva FM; Esteves de Oliveira É; Ferreira AP
Pulm Pharmacol Ther; 2017 Aug; 45():202-209. PubMed ID: 28689020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
